# Evaluation of the Effect of Telmisartan (Micardis® 80 mg/ MicardisPlus® 80/12.5 mg) on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients

> **NCT00904371** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 211 (actual)

## Conditions studied

- Hypertension
- Cardiovascular Diseases

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT00904371
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2011-01
- **Final completion:** —
- **Target enrollment:** 211 (ACTUAL)
- **Last updated:** 2012-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00904371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00904371, "Evaluation of the Effect of Telmisartan (Micardis® 80 mg/ MicardisPlus® 80/12.5 mg) on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00904371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*